When we evaluate a company, we ask a simple question: is this a faint signal of something that should exist? With BMI OrganBank, the answer was unusually clear. The need is enormous, the science is real, and the team is built to navigate the regulated path between them. Here is the case as we saw it.
A bottleneck measured in lives
Transplantation is one of modern medicine’s triumphs and one of its most constrained systems. The limiting factor is rarely surgical skill; it is supply and logistics, how many viable organs reach the right patient in time. Today, organs are often preserved with methods that give clinicians a narrow window and limited information. Viable organs are declined or lost not because they could not have helped someone, but because there was no way to keep them healthy long enough, or to assess them well enough to say yes with confidence.
Improve preservation and assessment, and you do not just move organs further, you let clinicians say yes more often.
A different approach to preservation
BMI OrganBank is advancing room-temperature perfusion, an approach designed to keep an organ physiologically active rather than merely cold and dormant. Beginning with the kidney, the system aims to extend the preservation window, maintain function, and generate data during preservation itself. That last point matters: an organ that can be monitored is an organ that can be assessed, and assessment is what turns a hesitant decline into an informed acceptance.
Why it fits our thesis
BMI sits at the center of where Sonnerie invests. It is a medical-device and life-sciences company in a regulated market, built on defensible, patented technology that emerged from a serious research institution. The path to patients runs through evidence and approval, exactly the kind of compliance-as-a-moat dynamic we believe rewards well-advised teams. And it is operator- and clinician-driven, which is how a company crosses the long distance from a working system to standard of care.
Where we hope to help
Our role at this stage is to be useful in the specifics: supporting the regulatory and commercialization strategy, opening doors across our network of operators and clinicians, and helping position the company for the partners and capital that will carry it forward. We invested alongside Mid Atlantic Bio Angels, and we’re glad to be in good company.
Most of all, BMI OrganBank reflects why we do this work. The best healthcare companies begin as quiet signals of a better way, and few are as worth amplifying as one that helps more transplants succeed.